PLENARY SPEAKER

 

Title: Discovery of Nitric Oxide and Cyclic GMP in Cell Signaling and Their Role in Drug Discovery and Development

Dr. Ferid Murad, M.D.

1998 Nobel Laureate in Physiology and Medicine
Lasker Awardee for Basic Research in Medicine
Professor in the Department of Biochemistry and Molecular Biology
George Washington University
Washington DC, USA

 

MEETING ORGANIZER

 

Dr. Harold C. Smith, Ph.D

Conference Chairman - Drug Discovery 2018
Department of Biochemistry and Biophysics
University of Rochester, School of Medicine and Dentistry, NY, USA
Fellow of the Royal Society of Biology
Founder and CEO, OyaGen, Inc, NY, USA

 

KEYNOTE SPEAKERS

Wendy Cornell, Ph.D.
Manager Drug Discovery Technologies (YKT)
IBM - Healthcare and Life Sciences Research, USA
Title: AI in Drug Target Identification and Drug Discovery
Troels Koch, Ph.D.
VP & Head of Research, RNA Therapeutics
Roche Innovation Center Copenhagen, Denmark
Title: New Drug Discovery Concepts for Locked Nucleic Acid (LNA) Therapeutics
Philips S. Low, Ph.D.
Presidential Scholar for Drug Discovery
Purdue University, IN, USA
Title: Sensitive Control of CAR T Cell Properties with Low Molecular Weight Drugs

SYMPOSIUM SPEAKERS

Michelle Arkin, Ph.D.
Co-director, Small Molecule Discovery Center (SMDC), San Francisco, CA, USA
Title: A Consortium-Based Approach to Academic Drug Discovery
Hashim M Al-Hashi, Ph.D.
Director, Duke Center for RNA Biology, Duke University, NC, USA
Title: Dynamic Ensemble-based Discovery of Small Molecules Targeting RNA
Ryan Bennett, Ph.D.
Chief Scientific Officer, OyaGen, Inc., Rochester NY, USA
Title: Drug Development Utilizing Targets within an Interactome
Jadwiga Bienkowska, Ph.D.
Oncology Translational Research, Pfizer, ORD, San Diego, CA, USA
Title: Watson Analytics: AI Research Assistant for Drug Discovery in Oncology
Christine Brideau, Ph.D.
Vice President, In Vitro Biology, Research Service Division (RSD), WuXi AppTec, NJ, USA
Title: Perspectives on building effective partnerships between CROs and Academia
Paul S. Brookes, Ph.D.
University of Rochester School of Medicine and Dentistry, NY, USA
Title: Role of Mitochondrial Complex II in Cardiac Ischemia, and Optimizing its Inhibition for Therapeutic Benefit
Dean G. Brown, Ph.D.
Director of External Chemistry, Hit Discovery, Discovery Sciences IMED Biotech Unit, AstraZeneca, MA, USA
Title: The use of an open innovation discovery model at AstraZeneca to access novel targets
Thomas D.Y. Chung, Ph.D.
Director, Translational Programs Outreach, SBP Medical Discovery Institute, CA USA
Title: Accelerating Translational Research into Drug Discovery in Academia through Strategic Partnerships
Dirk Daelemans, Ph.D.
KU Leuven, Rega Institute
Belgium
Title: Target deconvolution of small-molecules by CRISPR/Cas-mediated resistance mutagenesis scanning
Harris Andrew Gelbard, Ph.D.
University of Rochester School of Medicine and Dentisty, NY, USA
Title: Broad-spectrum Mixed Lineage Kinase Inhibition for Treatment of Multiple End Organ Diseases with Inflammation
Jennifer E. Golden, Ph.D.
University of Wisconsin-Madison, WI, USA
Title: Design and Development of First-In-Class Encephalitic Alphavirus Inhibitors with Prophylactic and Therapeutic In Vivo Efficacy
Rocco G. Gogliotti, Ph.D.
Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, TN, USA
Title: Cross-species expression profiling for improved target selection in Rett syndrome
Stine Jørgensen, Ph.D.
Senior Scientist, Vipergen ApS, Denmark
Title: Nanomolar inhibitor for hexamer DNA helicase RuvBL1/2 identified in DEL screen
Ailong Ke, Ph.D.
Department of Molecular Biology and Genetics, Cornell University, NY, USA
Title: Structure,mechanism, and potential applications of the Type I CRISPR-Cas system
Juergen Lademann, Ph.D.
Professor of Dermatology, Head - CCP, Berlin, Germany
Title: Drug Delivery with Nanoparticles – Science Fiction or Reality
Eric Martin, Ph.D.
Director, Computational Chemistry, Novartis Institutes for BioMedical Research, Inc., CA, USA
Title: Massively Multi-Target Profile-QSAR 2.0: Predictions as accurate as 4-point IC50s for most Novartis Assays
Hamid Mirzaei, Ph.D.
UT Southwestern Medical Center
TX, USA
Title: Hydralazine: A FDA Approved Drug with Multiple Therapeutic Targets
Howard Maibach, M.D.
Professor, UCSF School of Medicine, San Francisco, CA, USA
Title: Innovation from Academic Dermatology
Elliott Nickbarg, Ph.D.
Merck Research Laboratories, Boston, MA, USA
Title: Investigating Non-coding RNAs as Small Molecule Drug Targets using Afinity-Selection Mass Spectrometry
Stephanie C. Oestreich, MPA
EVP, Head BRIDGEs Partnerships North America, Evotec
Title: Bridging the Drug Discovery Gap
Whitney Smith, Ph.D.
Director, Business Development,
Collaborative Drug Discovery Inc., CA, USA
Title: Lessons Learned While Deploying Present and Developing Future Collaborative Informatics Innovations
Ravindra Peravali, Ph.D.
Head, Screening Center,
ITG, Karlsruhe Institute of Technology, Germany
Title: Zebrafish as a model organism for drug discovery and testing
Kamil Paruch, Ph.D.
Department of Chemistry, Masaryk University, Czech Republic
Title: Furo[3,2-b]pyridine – a novel privileged scaffold for highly selective kinase inhibitors and effective modulators of the Hedgehog pathway
Sunil Premawansa, Ph.D.
University of Colombo
Sri Lanka
Title: Involvement of Angiopoietin 1 and 2 in dengue patients specifically with respect to critical stage of dengue haemorrhagic fever
Adam R. Renslo, Ph.D.
Director of Chemistry, University of California, San Francisco, CA, USA
Title: Ferrous Iron Dependent Pharmacology in Cancer and Infectious Disease
Anuradha Roy, Ph.D.
Director, High Throughput Screening Laboratory
University of Kansas, KS, USA
Title: Early Drug Discovery in Academia
Johannes Reynisson, Ph.D.
School of Chemical Sciences, University of Auckland, New Zealand
Title: Virtual Screening for Novel Atg5-Atg16 Complex Inhibitors for Autophagy Modulation
Jikui Song, Ph.D.
University of California, Riverside
CA, USA
Title: Perspectives for Zika Virus NS5 Protein as a Drug Target
Paul C. Trippier, Ph.D.
Texas Tech University Health Sciences Center, TX, USA
Title: Multi-modal Small Molecule Therapeutic Development for Batten Disease
Susana Valente, Ph.D.
Department of Immunology and Microbiology, The Scripps Research Institute, FL, USA
Title: Silencing of the HIV Reservoir with a Potent Tat Inhibitor
Thomas Webster, Ph.D.
Northeastern University, MA, USA
Title: Antibiotic resistant bacteria, chemotherapeutic resistant cancer cells: Conventional drug therapy needs a nano face lift
Minhang Xin, Ph.D.
Xi’an Jiaotong University, P.R. China
Title: Novel 6-aryl substituted quinazoline derivatives as potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitors
Weian Zhao, Ph.D.
Sue and Bill Gross Stem Cell Research Center
University of California, Irvine, CA, USA
Title: Targeting Biophysical Cues to Study, Diagnose, and Treat Cancer

Participants

speaker image

Krishnan Chakravarthy

NanoAxis, LLC.
NY, USA
speaker image

Mukhtar Dauda

Bayero University
Nigeria
speaker image

Somlyai Gabor

HYD Pharma Inc.
Hungary
speaker image

Amiram Goldblum

The Hebrew University of Jerusalem
Israel
speaker image

Rajamma Mathew

New York Medical College
NY, USA
speaker image

Shadab Mohammad

King George’s Medical University
India
speaker image

Alan D. Rogol

University of Virginia Medical School
MD, USA
speaker image

Ram Samudrala

State University of New York
NY, USA
speaker image

Anavi-Goffer Sharon

Ariel University
Israel

Join Our Newsletter